Results support progression of EMERALD clinical trial of Resolution’s engineered macrophage therapy, RTX001Four-year follow-up data from the University of Edinburgh’s MATCH study, led by Resolution Therapeutics’ founder Professor Stuart Forbes, published in the journal Cell Stem CellResolution is pioneering engineered Regenerative Macrophage Therapy – which uses engineered macrophages designed to deliver a more potent and durable clinical effect, to treat a more severe patient population with hi

DELRAY BEACH, Fla., May 25, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Dental Implants and Prosthetics Market is projected to grow from about USD 12.79 billion in 2026 to USD 17.67 billion by 2031, at a CAGR of 6. 7%. Browse 550 market data Tables and 70 Figures spread through 500 Pages and in-depth TOC on 'Dental Implants and Prosthetics Market - Global Forecast to 2031' Dental Implants and Prosthetics Market Size & Forecast: Market Size Available for Years: 2025–2031 2026 Marke

In the Phase 1b Heart-2 trial, a single intravenous infusion of VERVE-102 produced dose-dependent lowering of PCSK9 and LDL-C, with both reductions sustained over follow-up of up to 18 months in participants at high risk for cardiovascular disease VERVE-102 is designed to mimic the protective effect of naturally occurring loss-of-function variants in PCSK9, which are associated with markedly lower lifetime risk of coronary heart disease Lilly plans to begin enrolling the Phase 2 clinical study o

VANCOUVER, BC, May 25, 2026 /PRNewswire/ -- Zero Candida (the "Company" or "ZCT"), (TSXV: ZCT) (OTC: ZCTFF) an Israeli FemTech medical device start-up, wishes to advise that it has elected to adopt semi-annual financial reporting (" SAR") in reliance on Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (" CBO 51-933"). Under the SAR framework, the Company will be exempt from filing interim financial reports and related Management's Discussion

Discover recent breakthroughs in AI, global connectivity, biopharma, and emergency care. JUPITER, Fla., May 25, 2026 /PRNewswire/ -- The award-winning educational series, Advancements with Ted Danson, will premiere a new episode on Saturday, May 30th at 8:00 PM ET, showcasing four compelling segments that explore how technology and innovation are shaping the future across industries. From artificial intelligence and digital infrastructure to biopharmaceutical developments and life-saving medica

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, May 25, 2026 (GLOBE NEWSWIRE) -- Grey Matters Health Inc. (the “Company” or “Grey Matters”) (CSE: GREY) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company, is pleased to announce that it has amended the warrant terms of its recently announced non-brokered private placement, removing the acceleration feature and extending the warrant exercise period to 3 years. All

Boey® has received a positive opinion from the CHMP for 30 EU & EEA markets If approved, Boey® has the potential to be the first and only botulinum neurotoxin serotype E that adult patients can try for the temporary improvement of Glabellar Lines Positive opinion is supported by data from two pivotal Phase 3 trials, which demonstrated rapid results as early as 8 hours and duration of 2-3 weeks2 NORTH CHICAGO, Ill., May 21, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV)

BERLIN, May 25, 2026 /PRNewswire/ -- MGI Tech Co. Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, is proud to announce that three of its latest innovations—the T1+ and T7+ gene sequencers and the Imabot™ EF6-CL handheld ultrasound—have been honored with the prestigious iF Design Award. Recognized for merging cutting-edge technology with intuitive aesthetics, these products underscore MGI's commitment to user-centric industria

Amai Proteins has achieved a major regulatory milestone with the Singapore Food Agency (SFA) approval of sweelin®, its flagship sweet protein, for use as a sweetening agent in food and beverage products. sweelin® is a next-generation sweet protein that enables significant sugar reduction and replaces conventional sweeteners with a protein-based alternative, designed to deliver superior clean taste, competitive cost, and improved formulation performance. REHOVOT, Israel, May 25, 2026 /PRNewswire/

STOCKHOLM, May 25, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi. According to Eisai's simulation, Leqembi sales will reach around JPY 300 billion (approximately SEK 17.6 billion) for the company's fiscal year (FY) 2028, which ends in March 2029. Eisai's presentation can be found on This is information that BioArctic AB (publ) is obliged to disclose pursuant t